Nuveen Asset Management LLC Has $402.17 Million Stake in Pfizer Inc. (NYSE:PFE)

Nuveen Asset Management LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 3.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,158,966 shares of the biopharmaceutical company’s stock after selling 621,603 shares during the period. Nuveen Asset Management LLC owned 0.27% of Pfizer worth $402,167,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in PFE. Fiduciary Alliance LLC boosted its holdings in shares of Pfizer by 15.5% during the fourth quarter. Fiduciary Alliance LLC now owns 9,803 shares of the biopharmaceutical company’s stock worth $260,000 after acquiring an additional 1,319 shares during the period. Rosenberg Matthew Hamilton boosted its holdings in shares of Pfizer by 59.9% during the fourth quarter. Rosenberg Matthew Hamilton now owns 2,029 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 760 shares during the period. Mayfair Advisory Group LLC boosted its stake in Pfizer by 4.7% in the 4th quarter. Mayfair Advisory Group LLC now owns 10,758 shares of the biopharmaceutical company’s stock valued at $285,000 after purchasing an additional 479 shares during the period. 626 Financial LLC boosted its stake in Pfizer by 15.4% in the 4th quarter. 626 Financial LLC now owns 48,849 shares of the biopharmaceutical company’s stock valued at $1,296,000 after purchasing an additional 6,514 shares during the period. Finally, Accurate Wealth Management LLC boosted its stake in Pfizer by 17.6% in the 4th quarter. Accurate Wealth Management LLC now owns 35,736 shares of the biopharmaceutical company’s stock valued at $955,000 after purchasing an additional 5,360 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Down 3.8%

PFE stock opened at $22.01 on Thursday. The stock has a market capitalization of $125.13 billion, a P/E ratio of 15.61, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a 50-day moving average price of $23.80 and a 200-day moving average price of $25.44.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.82 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.81%. Pfizer’s dividend payout ratio is presently 124.64%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on PFE shares. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.